Quick Answer
Disc Medicine, Inc. reported Stockholders Equity of $739.83 million for the year ending 2025.
- Disc Medicine, Inc. showed an increase of +66.8% in Stockholders Equity from 2024 to 2025.
- This data is from Disc Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $10.0 thousand | Q2 2020: -$6.62 million | Q3 2020: -$8.28 million | Q1 2021: $171.16 million | Q2 2021: $157.68 million | Q3 2021: $140.86 million | Q1 2022: -$73.67 million | Q2 2022: -$82.78 million | Q3 2022: -$98.53 million | Q1 2023: $232.86 million | Q2 2023: $371.22 million | Q3 2023: $358.97 million | Q1 2024: $338.07 million | Q2 2024: $488.83 million | Q3 2024: $467.96 million | Q1 2025: $660.36 million | Q2 2025: $614.17 million | Q3 2025: $573.39 million.
- Over the full 7 years of available data (2019 to 2025), Disc Medicine, Inc.'s Stockholders Equity has grown by 7,191.9%.
- Historical annual values: Fiscal year 2025: $739.83 million | Fiscal year 2024: $443.59 million | Fiscal year 2023: $345.12 million | Fiscal year 2022: $176.60 million | Fiscal year 2021: -$64.20 million | Fiscal year 2020: -$28.81 million | Fiscal year 2019: -$10.43 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: